Author

Lisa A. Newman

Weill Cornell MedicineORCID 0000-0003-2059-0477Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1 Assay:organoid / primary culture· 1

Frequent Co-Authors

Adriana IrizarryiD· 2 shared Andrea SboneriD· 2 shared Florencia P. Madorsky RowdoiD· 2 shared Jenna E. MoyeriD· 2 shared John NguyeniD· 2 shared Juan Miguel MosqueraiD· 2 shared Jyothi ManohariD· 2 shared M. Laura MartíniD· 2 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Adriana IrizarryORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintApr 10, 2025

Pan-Cancer PDOs Preserve Tumor Heterogeneity and Uncover Therapeutic Vulnerabilities

Hui–Hsuan Kuo, Bhavneet Bhinder, Hamza Numan Gokozan…·M. Laura Martín

This study develops a pan-cancer PDO platform to preserve tumor heterogeneity and identify therapeutic vulnerabilities, finding that 58% of PDOs respond to Talazoparib and combination screens reveal resistance-overcoming drugs.

DOI 10.1101/2025.04.10.647635

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologyCancer ResearchPeer-reviewedFeb 1, 2025

Kinome focused CRISPR-Cas9 screens in African ancestry patient-derived breast cancer organoids identifies essential kinases and synergy of EGFR and FGFR1 inhibition.

Florencia P. Madorsky Rowdo, Rachel N. Martini, Sarah E. Ackermann…·M. Laura Martín

The paper uses CRISPR-Cas9 screens in breast cancer organoids from African ancestry patients to identify essential kinases and show synergy between EGFR and FGFR1 inhibitors.

23 citationstop 3%

humanorganoid / primary culture

𝕏 PostBluesky